Decheng Capital LLC Zentalis Pharmaceuticals, Inc. Transaction History
Decheng Capital LLC
- $356 Billion
- Q1 2025
A detailed history of Decheng Capital LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Decheng Capital LLC holds 2,019,762 shares of ZNTL stock, worth $2.75 Million. This represents 0.9% of its overall portfolio holdings.
Number of Shares
2,019,762
Previous 2,338,095
13.62%
Holding current value
$2.75 Million
Previous $7.08 Billion
54.67%
% of portfolio
0.9%
Previous 1.52%
Shares
5 transactions
Others Institutions Holding ZNTL
# of Institutions
144Shares Held
65.9MCall Options Held
43.2KPut Options Held
21.7K-
Matrix Capital Management Company, LP Waltham, MA14MShares$19 Million2.05% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$6.55 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.48MShares$6.09 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$4.45 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.22MShares$4.37 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $77.5M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...